New perspectives in lung cancer. 2. Growth factors and lung cancer.

per Woll, P J
Publicat 1991

Growth factors, antagonists and lung cancer.

per Woll, P J
Publicat 1993

Cytokine Therapy

per Woll, P.J.
Publicat 1993

Neuropeptide growth factors and cancer.

per Woll, P. J.
Publicat 1991

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro.

per Woll, P J, Rozengurt, E
Publicat 1988

Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer.

per Woll, P. J., Rozengurt, E.
Publicat 1988

Persistent back pain due to malignant lymphadenopathy.

per Woll, P J, Rankin, E M
Publicat 1987

Totally implantable vascular access for long term chemotherapy.

per Woll, P J, Rubens, R D
Publicat 1986

Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1β and hypoxia in small cell lung cancer

per Zhu, Y M, Bagstaff, S M, Woll, P J
Publicat 2006

Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer

per Coulson, J M, Stanley, J, Woll, P J
Publicat 1999

Pericardial effusion complicating breast cancer.

per Woll, P J, Knight, R K, Rubens, R D
Publicat 1987

Interleukin-8/CXCL8 is a growth factor for human lung cancer cells

per Zhu, Y M, Webster, S J, Flower, D, Woll, P J
Publicat 2004

E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer.

per Coulson, J M, Fiskerstrand, C E, Woll, P J, Quinn, J P
Publicat 1999

Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom

per Gerrand, C. H., Billingham, L. J., Woll, P. J., Grimer, R. J.
Publicat 2007

Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

per Coleman, R. E., Woll, P. J., Miles, M., Scrivener, W., Rubens, R. D.
Publicat 1988

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide

per Young, R J, Tin, A W, Brown, N J, Jitlal, M, Lee, S M, Woll, P J
Publicat 2012

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey

per Lebret, T., Casas, A., Cavo, M., Woll, P.J., Deleplace, C., Kennedy, C., Schoen, P., Jackisch, C.
Publicat a Eur J Cancer Care (Engl) (2016)

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

per Woll, P. J., Crowther, D., Johnson, P. W., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., Newlands, E. S.
Publicat 1995

Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.

per Woll, P. J., Basser, R., Le Chevalier, T., Drings, P., Perez Manga, G., Adenis, A., Seymour, L., Smith, F., Thatcher, N.
Publicat 1997

Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes

per Taylor, G M, Gokhale, D A, Crowther, D, Woll, P J, Harris, M, Ryder, D, Ayres, M, Radford, J A
Publicat 1999